Greenery May Be the Secret to Slowing the Biological Aging Process – At Least for Women

17 mins read

We all know being surrounded by greenery is good for the mind and soul, but can it be good for the body, too?

Planetary health researchers at Monash University’s School of Public Health and Preventive Medicine have found that may indeed be the case, at least for women.

In a world first, they’ve shown a link between the amount of plant life in a person’s immediate environment and slower biological aging, based on changes to DNA methylation.

“We searched the medical literature prior to embarking on this project,” says PhD candidate and first author Rongbin Xu, “and could only find a single abstract, presented at a conference but never written up and published in a peer-reviewed journal, that touched on this subject.

“It focused on infants, and compared their biological gestational age with the greenness surrounding the mother during pregnancy, so it was quite a different application to our current study.”

Their study was recently published in Environmental Health Perspectives.

With an aging global population driven by increased longevity and falling birth rates, understanding how to prolong good health and functioning into old age is a priority.

One of the most robust markers of biological aging is the aging-related methylation changes found in an individual’s DNA. This is where some sections of DNA become covered by methyl molecules.

The role of methylation
Some sections of DNA have CpG sites that are particularly prone to increased methylation with age, and this restricts the functionality of affected genes. Conversely, aging can also reduce methylation in other areas, leading to over-expression of genes, which can be equally as harmful.

DNAmAge is a measure of a person’s biological age as measured by methylation, and there are four main algorithms in popular use to calculate it: Horvath’s Age, Hannum’s Age, PhenoAge, and GrimAge.

There’s a growing body of research that indicates GrimAge may be the most robust DNAmAge estimator, given its strong predictive power of future health, such as time to death, cancer, and heart diseases.

DNA Code on Leaf

By comparing an individual’s DNAmAge to their chronological age in years, researchers can calculate the acceleration of biological aging (DNAmAgeAC). Increased acceleration is associated with early death and numerous diseases of aging, such as cancer and heart disease.

While some methylation changes are inevitable, we actually do have some influence over it. Research shows that interventions such as dietary adjustments and environmental factors may reverse adverse methylation changes.

“We speculated that the amount of greenery in a person’s immediate environment may play a role in reducing accelerated biological aging,” says Rongbin.

“A high degree of local vegetation density – gardens, parkland, bush – can reduce mental stress, provide a space for social interaction, encourage physical activity and reduce harm from air pollution and heat. Given these are all determinants for good health, it made sense that there may be a connection.”

The researchers leveraged existing data from the Australian Mammographic Density Twins and Sisters Study, which had previously explored the links between environmental, genetic and lifestyle factors and breast tissue density, a known risk factor for breast cancer.

Initial trial participants included female twins aged 40-70 years in Perth, Sydney, and Melbourne, and the cohort was later expanded to include their non-twin sisters. Blood samples were collected and stored as Guthrie cards, much like is done for newborn babies.

These cards formed the source for the DNA methylation analysis performed as part of this current study. Methylation levels were analyzed in a laboratory, and four DNAmAges were calculated for each of 479 women from 130 different families, using the four algorithms mentioned above.

The second part of the project involved mapping vegetation levels near participants’ homes. Those taking part had provided residential addresses for the study, which were converted to longitude-latitude coordinates using a Google Maps interface.

While there’s a risk some participants may have moved house during that time, a national Australian survey in 2008 showed 80% in this age group hadn’t moved house for more than five years.

The team used infrared and visible light readings from a NASA satellite to estimate local vegetation mass in the 12 months leading up to each participant’s blood draw.

Plant life absorbs visible red light for photosynthesis, but strongly reflects infrared and near-infrared light. The researchers used this – and some fairly complex mathematical formulas that accounted for atmospheric distortion in light readings – to estimate greenness density up to 2km from their homes.

“We found that using the most robust of the algorithms, GrimAge, increased surrounding greenness was associated with slower biological aging,” says Rongbin. “Our study shows that a 0.1-unit increase in the Normalised Difference Vegetation Index within 500 meters of home is associated with a 0.31-years reduction in biological aging as measured by GrimAge.

“Previous cohort studies tell us this is equivalent to a 3% reduction in all-cause mortality. The association remained stable when measuring greenness at 300 meters, one kilometer and two kilometers from home.”

Three components of GrimAge showed particularly strong association with slowed biological aging:

Greenness is associated with a reversal of DNA methylation changes arising from exposure to cigarette smoke
Greenness may be associated with improved immune function and metabolic health as indicated by the biomarker GDF-15
Greenness may be associated with a reduction in fatty tissues seen in obesity, and improved kidney health as indicated by the biomarker cystatin.
“More research is needed to confirm our results in larger studies,” says Rongbin, “and to look at the process in men, but it’s an exciting foray into this field.”

Reference: “Surrounding Greenness and Biological Aging Based on DNA Methylation: A Twin and Family Study in Australia” by Rongbin Xu, Shuai Li, Shanshan Li, Ee Ming Wong, Melissa C. Southey, John L. Hopper, Michael J. Abramson and Yuming Guo, 30 August 2021, Environmental Health Perspectives.A new Covid-19 treatment for people with diabetes has shown promising results in a trial led by UCL researchers.

The trial was conducted by St George Street Capital (SGSc) — a medical research charity — with the goal to find new purposes, where there is a real clinical need, for drugs that have already passed safety checks

Professors John Martin (UCL Division of Medicine) and Pete Coffey (UCL Institute of Ophthalmology) founded the charity along with an American philanthropist to trial new medicines four years ago. They focused on a number of medicines shown to be safe in phase I clinical trials which had been abandoned by the pharmaceutical industry, but may still be beneficial for other purposes.

Over the last year, SGSc have been trialing a drug (AZD1656) in diabetic patients. The drug was gifted to the charity by Astra Zeneca. The team recognized that it could activate cells from the immune system as a potential treatment for people with the SARS-CoV-2 virus by dampening the overactive response of the immune system which causes damage to the organs in the body, particularly the heart and lungs.

The trial reduced the number of deaths in patients receiving AZD1656, a promising finding which will need to be analyzed further by the researchers, when cellular immunology results become available, before the study results undergo peer review. The reduced mortality for patients on AZD1656 was observed on top of benefits from other medications, such as dexamethasone, as part of standard of care. AZD1656 was shown to be well-tolerated with no serious adverse reactions occurring.

Diabetes, whether type 1 or 2, has been the leading single cause of co-morbidity during the pandemic and one in three of all deaths with Covid-19 in hospitals in England have been associated with diabetes.

The objectives of the clinical trial, called ARCADIA, were to assess the efficacy, safety, and tolerability of the drug, a glucokinase activator, and to determine the effect of the therapy on clinical improvement and mortality.

The recently completed ARCADIA phase ll trial, led by St George Street Capital, was randomized, double-blind, placebo-controlled and carried out in 158 patients. The trial was funded by international investment and the UKRI/Innovate UK program.

The researchers say their data supports continued investigation of AZD1656 for the treatment of people with diabetes who have Covid-19 in future clinical trials. They also hope to trial the drug in people without diabetes potentially benefiting an even larger group of people such as patients with long Covid.

Professor Martin, Chairman of SGSC and Principal Investigator on the UKRI grant said: “We have demonstrated our ability to rapidly deliver a clinical trial in 16 months from conception to completion. The promising results from this trial indicate that AZD1656, a simple oral tablet, has the potential to become a new treatment for Covid-19. It is beneficial regardless of viral mutations. It is the first specific treatment for Covid disease (as opposed to antivirals or vaccines) and may herald a new field of drugs activating cells in the body which become themselves the therapeutic agent.”

Professor Coffey added: “Our study demonstrates the potential outcomes of partnerships with pharma in repurposing drugs for use in unmet clinical need is immense. St George Street Capital has proven this model.”

On Thursday this week, the team’s work was recognized at a reception at 10 Downing Street attended by Professor Martin. The reception was held to celebrate the UK-United Arab Emirates prosperity and innovation partnership, as the UAE’s sovereign wealth fund contributed to the trial’s funding.


Leave a Reply

Your email address will not be published.

Previous Story

Right Light on the Mother’s Belly May Be Important to Fetal Brain Development

Next Story

Methamphetamine-Involved Overdose Deaths Nearly Tripled in the United States Between 2015 to 2019